Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Yutkin

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|December 23, 2011
Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancerVladimir Yutkin, Joseph Chin
Urology|December 3, 2014
Reply: To PMID 25443920Vladimir Yutkin, Joseph L Chin
Expert Review of Anticancer Therapy|June 18, 2010
Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?Vladimir Yutkin, Benjamin Nisman, Dov Pode
The Journal of Urology|October 20, 2007
The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot studyVladimir Yutkin, Dov Pode, Eli Pikarsky, et al.
Expert Opinion on Biological Therapy|September 7, 2017
Immunotherapy options for painful bladder syndrome: what's the potential?Ioannis Mykoniatis, Ioannis Katafigiotis, Stavros Sfoungaristos, et al.
Harefuah|September 11, 2025
[THE SURGICAL TREATMENT OF BENIGN HYPERPLASIA OF THE PROSTATE - REVIEW, INNOVATIONS AND TRENDS]Amitay Lorber, Eyal Atias, Vladimir Yutkin, et al.
Histology and Histopathology|October 15, 2024
Collagen fiber arrangement in the normal bladder lamina propria and their potential impact on the pathological substaging of bladder cancer stage T1Ofer N Gofrit, Vladimir Yutkin, Mordechai Duvdevani, et al.
Expert Opinion on Pharmacotherapy|April 18, 2015
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical optionsStavros Sfoungaristos, Ofer N Gofrit, Vladimir Yutkin, et al.
Cells|February 12, 2026
Targeting Bladder Cancer with Inactivated Uropathogenic <i>E. coli</i>: A Novel Alternative to BCG ImmunotherapyVladimir Yutkin, Naseem Maalouf, Chamutal Gur, et al.
Frontiers in Cellular and Infection Microbiology|September 19, 2022
High mannose level in bladder cancer enhances type 1 fimbria-mediated attachment of uropathogenic <i>E. coli</i>Naseem Maalouf, Chamutal Gur, Vladimir Yutkin, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|December 23, 2011
Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancerVladimir Yutkin, Joseph Chin
Urology|December 3, 2014
Reply: To PMID 25443920Vladimir Yutkin, Joseph L Chin
Expert Review of Anticancer Therapy|June 18, 2010
Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?Vladimir Yutkin, Benjamin Nisman, Dov Pode
The Journal of Urology|October 20, 2007
The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot studyVladimir Yutkin, Dov Pode, Eli Pikarsky, et al.
Expert Opinion on Biological Therapy|September 7, 2017
Immunotherapy options for painful bladder syndrome: what's the potential?Ioannis Mykoniatis, Ioannis Katafigiotis, Stavros Sfoungaristos, et al.
Harefuah|September 11, 2025
[THE SURGICAL TREATMENT OF BENIGN HYPERPLASIA OF THE PROSTATE - REVIEW, INNOVATIONS AND TRENDS]Amitay Lorber, Eyal Atias, Vladimir Yutkin, et al.
Histology and Histopathology|October 15, 2024
Collagen fiber arrangement in the normal bladder lamina propria and their potential impact on the pathological substaging of bladder cancer stage T1Ofer N Gofrit, Vladimir Yutkin, Mordechai Duvdevani, et al.
Expert Opinion on Pharmacotherapy|April 18, 2015
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical optionsStavros Sfoungaristos, Ofer N Gofrit, Vladimir Yutkin, et al.
Cells|February 12, 2026
Targeting Bladder Cancer with Inactivated Uropathogenic <i>E. coli</i>: A Novel Alternative to BCG ImmunotherapyVladimir Yutkin, Naseem Maalouf, Chamutal Gur, et al.
Frontiers in Cellular and Infection Microbiology|September 19, 2022
High mannose level in bladder cancer enhances type 1 fimbria-mediated attachment of uropathogenic <i>E. coli</i>Naseem Maalouf, Chamutal Gur, Vladimir Yutkin, et al.
Pageof 8